If healthspan is the goal — living more years feeling strong, mobile, and metabolically resilient — we need to talk about obesity differently. The old story of simply eating less and moving more ignores the biology. Obesity is a chronic, multifactorial disease with powerful genetic, hormonal, and environmental drivers. Like other chronic diseases, it often benefits from long-term medical therapy alongside nutrition, movement, sleep, and psychological support.
This is where incretin-based medicines come in. GLP-1 receptor agonists such as semaglutide (Wegovy) and the dual GIP/GLP-1 agonist tirzepatide (Mounjaro) work by changing physiology — appetite, satiety, and gastric emptying — to shift energy balance in ways most people can genuinely feel. For many, they act like noise-cancelling headphones on hunger, creating the conditions to build durable habits that extend healthspan.
What the Evidence Actually Shows
Semaglutide 2.4mg weekly (with lifestyle support) produced approximately 15% mean weight loss in adults with overweight or obesity over 68 weeks in the STEP-1 randomised controlled trial — one of the most robust weight management trials ever conducted.
Tirzepatide achieved approximately 16 to 23% mean weight loss at 72 weeks in the SURMOUNT-1 trial, making it the most effective pharmacological weight management option currently available.
Beyond weight: in people with established cardiovascular disease without diabetes, semaglutide 2.4mg significantly reduced major adverse cardiovascular events compared to placebo in the SELECT trial — a landmark finding that repositioned these medicines as disease-modifying therapies, not cosmetic aids.
These medicines are not cosmetic aids. They are disease-modifying therapies with benefits that extend well beyond the number on the scale — and that is exactly what healthspan means in practice.
The Lifelong Medication Question — and Why Stopping Often Leads to Regain
When people stop GLP-1 therapy, weight regain is common. In the STEP-4 withdrawal study, participants who continued semaglutide after an initial run-in period maintained and deepened their weight loss, while those switched to placebo regained most of it — despite ongoing lifestyle support. This mirrors what we see with other chronic conditions: hypertension requires ongoing management, dyslipidaemia requires ongoing management, and obesity often does too.
This does not mean everyone must take these medicines indefinitely. It means planning for long-term management — whether through ongoing medication, structured maintenance strategies, or both — rather than treating these as 12-week sprints. The Endocrine Society frames obesity pharmacotherapy as an adjunct to comprehensive care that is appropriate long-term when effective and well-tolerated.
How These Medicines Work
GLP-1 and GIP receptor agonists amplify your body's natural satiety signals in the brain and slow stomach emptying in the gut. The result is that you feel full sooner and stay full longer — without requiring constant willpower to override hunger. Over time, this leads to lower total caloric intake and meaningful weight loss. As weight falls, metabolic risk markers including blood pressure, blood lipids, and liver fat typically improve in parallel.
Safety, Side Effects, and Who Should Avoid Them
Nausea, reflux, early fullness, constipation, and diarrhoea are most common during dose escalation and typically improve over time. Slow titration significantly reduces their impact — this is not a medicine to rush.
Gallbladder events and, rarely, pancreatitis have been reported. These medicines carry a warning regarding medullary thyroid carcinoma risk observed in animal studies — they should be avoided in people with a personal or family history of medullary thyroid carcinoma or MEN-2 syndrome. Always discuss your full medical history with your prescribing clinician.
Protein-forward meals help preserve lean muscle mass during weight loss. Resistance training is particularly important for the same reason. Prioritising sleep and working with a clinician and dietitian alongside the medication produces significantly better and more durable outcomes than medication alone. Guidelines are clear: medication plus lifestyle, not either/or.
Australia-Specific Information
Wegovy (semaglutide 2.4mg) is TGA-approved in Australia for chronic weight management. Since 2025 it also carries approval for reducing cardiovascular events in people with overweight or obesity and established cardiovascular disease — a significant expansion of its indicated use.
PBS subsidy for obesity indications was not listed as of mid-2025, meaning out-of-pocket costs remain substantial for most Australians. This is an active area of health policy discussion, and the landscape may change. Your GP or specialist can provide the most current information on access and cost for your situation.
Changing the Narrative: Obesity Care as a Starting Line for Healthspan
If your biology keeps pulling you back toward a higher weight set-point, willpower alone is an unfair fight against a physiological force. Treating obesity as a medical condition with medical tools is not giving up — it is gearing up. For many people, GLP-1 therapy provides the metabolic stability to build the habits that genuinely extend healthspan: strength training, protein-centred eating, fibre, post-meal walking, and better sleep. Those habits then compound into lower visceral fat, improved mobility, healthier blood pressure and lipids, and fewer cardiovascular events.
Medication can quiet the hunger and lower the biological headwinds. You bring the daily habits — food, movement, sleep, stress management. Together, that is a healthspan engine: sustainable, compassionate, and personalised.
Getting Started: A Conversation With Your GP or Specialist
- Assess candidacy. Your clinician will consider BMI, existing health conditions, medications, and your full medical history to determine whether these medicines are appropriate for you.
- Map a plan. A clear dose-escalation schedule, strategies for managing side effects, and a parallel nutrition and movement plan significantly improve outcomes.
- Think long-term. If the medicine is effective and well-tolerated, plan for maintenance rather than a predetermined stop date. Chronic conditions benefit from ongoing management.
- Review beyond the scale. Track waist circumference, blood pressure, blood lipids, sleep quality, and mobility alongside weight. These are all dimensions of healthspan — and they are all worth measuring.
This article is general information only and is not personal medical advice. Always discuss your individual risks, benefits, and treatment options with your GP or specialist, who can provide personalised recommendations based on your health status, medical history, and circumstances.